San Antonio Breast Cancer Conference 2013 - Second-Generation Gene Expression Tests Compared: Most prognostic information provided by EPclin
(firmenpresse) - (DGAP-Media / 13.12.2013 / 14:33)
San Antonio (USA)- Which gene expression test for breast
cancer patients adds the most additional prognostic information to common
clinical parameters? The Spanish Breast Cancer Research Group (GEICAM) has
compared the standardized test for pathology laboratories EndoPredict (EP)
and research-based versions of the PAM50 assay. The result: EPclin adds
prognostic information beyond the research-based versions of the PAM50
test, likely because EPclin includes information about patient node status.
The results were now presented at the San Antonio Breast Cancer Conference.
Various gene expression analysis kits are now available to provide reliable
prognostic guidance in breast cancer. EndoPredict and PAM50 (Prosigna) are
second-generation multigene tests. These test kits are used to determine an
individual patient's prognosis and thereby decide whether breast cancer
patients require chemotherapy or not. In contrast to older forerunners,
this current test generation also detects the likelihood of late
metastases, i.e. metastasis formation after more than five years, and can
thus also be used to address the question of the usefulness of extended
anti-hormone therapy.
As part of the GEICAM/9906 sub-study, the molecular scores were measured
and combined with the respective clinical data (for PAM50, with tumour
size; for EP, with tumour size and nodal status) to determine the hybrid
scores according to the test design. All results were found to be
significantly prognostic; both tests allowed identification of a low-risk
group with very few relapses within the ten years post diagnosis.
'The low-risk group was determined with the EPclin and ROR-PT hybrid
scores. Of the patients with a low risk according to ROR-PT, 8% developed
metastases within ten years, while in the low-risk group according to
EPclin there were no relapses at all', explained Prof. Dr. Miguel Martin,
chairman of the GEICAM Research Group.
A direct comparison showed that all signatures added prognostic information
to common clinical parameters, but only EPclin, compared to the other
scores, provides additional information for predicting the likelihood of
metastasis.
'The superior performance of EPclin compared to the research-based PAM50
could be due to the inclusion of the patient's nodal status. Thus, the
prognostic value of genetic signatures can be further improved by
integration of clinical risk factors,' said Prof. Martin.
The two methods were compared on the basis of 536 tumour samples (all ER+ /
HER2-, node-positive). All the patients were treated with chemotherapy
followed by anti-hormonal therapy.
Specifically, the EndoPredict (EP) score and two versions of the PAM50
score (the subtype-based ROR-S score and the additionally
proliferation-based ROR-P) were measured. In addition, the necessary
clinical information was supplemented to obtain the: a) ROR-T score (ROR-S
and tumour size), b) ROR-PT score (ROR-P and tumour size) and c) EPclin
score (EP score, tumour size and nodal status).
Company portrait
Sividon Diagnostics GmbH was founded in July 2010 as a management buyout
from Siemens Healthcare Diagnostics Products in Cologne, Germany. The
company aims to sustainably increase the quality of therapy-accompanying
diagnostics in oncology. EndoPredict(R), the first diagnostic test from
Sividon, has been available since 2011. The breast cancer prognostic test
helps in deciding for which patient a chemotherapy is indicated.
For further information, visit www.sividon.com.
End of Media Release
---------------------------------------------------------------------
Issuer: Sividon Diagnostics GmbH
Key word(s): Health
13.12.2013 Dissemination of a Press Release, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
244725 13.12.2013
Themen in dieser Pressemitteilung:
san-antonio-breast-cancer-conference-2013
second
generation-gene-expression-tests-compared-most-prognostic-information-provided-by-epclin
Unternehmensinformation / Kurzprofil:
Datum: 13.12.2013 - 14:33 Uhr
Sprache: Deutsch
News-ID 324187
Anzahl Zeichen: 5222
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 434 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"San Antonio Breast Cancer Conference 2013 - Second-Generation Gene Expression Tests Compared: Most prognostic information provided by EPclin"
steht unter der journalistisch-redaktionellen Verantwortung von
Sividon Diagnostics GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
